Amarantus Announces Three Data Presentations Related to the Company's LymPro Diagnostic Test at the Alzheimer's Association I...
July 07 2014 - 8:30AM
Amarantus BioScience Holdings, (OTCQB:AMBS), a biotechnology
company focused on the discovery and development of novel
diagnostics and therapeutics related to endoplasmic reticulum
stress, cell cycle dysregulation, neurodegeneration and apoptosis,
today announced that analytical performance, clinical performance
and 6-year longitudinal data related to the Company's LymPro Test®
will be presented at the Alzheimer's Association International
Conference (AAIC), held at the Bella Center in Copenhagen, Denmark,
July 12-17, 2014.
"We are pleased to be presenting data on three critical aspects
of LymPro's diagnostic profile," said Gerald E. Commissiong,
President & CEO of Amarantus. "It is critical to properly
position LymPro within the scientific community as we advance
towards commercialization. We believe this data will provide the
basis for pharmaceutical companies to use LymPro initially as a
surrogate marker in their trials and for Key Opinion Leaders to add
LymPro as a tool in their diagnostic paradigm. These key
constituents will be critical for LymPro's initial market
adoption."
Poster Presentation
Details |
Date: July 14 2014 |
Location: Exhibit Hall (Bella Center
Convention Center) |
Poster Session Time: 11:45a.m. -
2:15 p.m. |
Session
Type: AAIC Poster Presentation |
Proposal Number: 45402 |
Presentation Title: Employing Lymphocyte
Proliferation as a means to Asses Cell Cycle Dys-regulation in
Cognitively Impaired Subjects: Clinical Performance of the LymPro
Assay |
Poster Number: P2-389 |
|
Date: July 15, 2014 |
Location: Exhibit Hall (Bella Center
Convention Center) |
Poster Session Time: 11:45 a.m. – 2:15
p.m. |
Session Type: AAIC Poster
Presentation |
Proposal Number: 45240 |
Presentation Title: Retrospective Analysis of
Clinical Prognosis of Subjects from a 2008 study using the LymPro
assay |
Poster Number: P3-118 |
|
Date: July 15, 2014 |
Location: Exhibit Hall (Bella Center
Convention Center) |
Poster Session Time: 11:45 a.m. –
2:15p.m. |
Session Type: AAIC :Poster Presentation |
Proposal Number: 45398 |
Presentation Title: Employing Lymphocyte
Proliferation as a means to Asses Cell Cycle Dys-regulation in
Cognitively Impaired Subjects: Analytical Performance of the LymPro
Assay |
Poster Number: P3-117 |
About LymPro Test
The Lymphocyte Proliferation Test (LymPro Test ®) is a
diagnostic blood test that measures the ability of peripheral blood
lymphocytes to withstand an external stimulation inducing them to
enter the cell cycle. It is hypothesized that certain diseases are
the result of a compromised cellular machinery that leads to
abhorrent cell cycle re-entry by neurons. The inventive step for
LymPro involves using peripheral blood lymphocytes (PBLs) as a
surrogate for neuronal cell function, suggesting a common
immune-based relationship between PBLs and neurons in the brain.
LymPro Test ® is currently being developed as a diagnostic blood
test for Alzheimer's disease and is being evaluated as a diagnostic
blood test for Traumatic Brain injury and Chronic Traumatic
Encephalopathy.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases associated with
neurodegeneration and protein misfolding-related apoptosis. AMBS
has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small
molecule indicated for Parkinson's Levodopa induced dyskinesia and
Adult ADHD. AMBS has an exclusive worldwide license to the
Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's
disease and owns the intellectual property rights to a therapeutic
protein known as Mesencephalic-Astrocyte-derived Neurotrophic
Factor ("MANF") and is developing MANF-based products as treatments
for brain disorders. AMBS also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). Amarantus operations are
located at Janssen Labs @QB3 in San Francisco, CA. For further
information please visit www.Amarantus.com, or connect with the
Company on Facebook, LinkedIn, Twitter and Google+.
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements." These forward-looking statements
generally are identified by the words believes," project,"
expects," anticipates," estimates," intends," strategy," plan,"
may," will," would," will be," will continue," will likely result,"
and similar expressions. Forward-looking statements are based on
current expectations and assumptions that are subject to risks and
uncertainties which may cause actual results to differ materially
from the forward-looking statements. Our ability to predict results
or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on
our operations and future prospects on a consolidated basis
include, but are not limited to: changes in economic conditions,
legislative/regulatory changes, availability of capital, interest
rates, competition, and generally accepted accounting principles.
These risks and uncertainties should also be considered in
evaluating forward-looking statements and undue reliance should not
be placed on such statements.
CONTACT: Amarantus Bioscience Holdings, Inc.:
Aimee Boutcher, Investor Relations
408.737.2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024